Nu-Med Plus, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020
August 19, 2020 at 05:09 pm EDT
Share
Nu-Med Plus, Inc. announced earnings results for the second quarter ended June 30, 2020. For the second quarter, the company announced operating loss was USD 904,446 compared to USD 243,785 a year ago. Net loss was USD 908,467 compared to USD 248,184 a year ago. Basic loss per share from continuing operations was USD 0.02. For the half year, operating loss was USD 1.053 million compared to USD 667,513 a year ago. Net loss was USD 1.061 million compared to USD 676,379 a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.01 a year ago.
Nu-Med Plus, Inc. is a medical device company, which is principally engaged in the designing, development, enhancement and commercialization of later-stage medical devices. The Company is focused on the creation of a nitric oxide generating formulation, a hospital bedside nitric oxide (NO) delivery system, a clinical unit for use in medical clinics and rehabilitation centers and a mobile rechargeable device to deliver nitric oxide gas to offer solutions to hospitals, health systems and the medical community throughout the world. Hospital NO Unit delivers a continuous intra-breath concentration of therapeutic NO to patients who are on a ventilator in a hospital setting. Clinical Delivery System is a simplified version of the hospital unit. Portable Delivery System delivers high purity NO to the patient at prescribed intervals for 24 hours per day at controlled doses by means of a nasal cannula or a face mask. Reagent Delivery provides a range of concentrations and flow rates of NO.
NU-MED PLUS, INC. 
